Detalhe da pesquisa
1.
Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE).
Antimicrob Agents Chemother
; 67(4): e0119322, 2023 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36975790
2.
Comparison of Occlusive and Open Application in a Psoriasis Plaque Test Design, Exemplarily Using Investigations of Mapracorat 0.1% Ointment versus Vehicle and Reference Drugs.
Skin Pharmacol Physiol
; 30(2): 102-114, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28407625
3.
ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment.
PLoS Negl Trop Dis
; 17(6): e0011440, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37352322
4.
Nifurtimox for Treatment of Chagas Disease in Pediatric Patients: the Challenges of Applying Pharmacokinetic-Pharmacodynamic Principles to Dose Finding.
AAPS J
; 24(5): 92, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36002604
5.
Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina.
PLoS Negl Trop Dis
; 15(10): e0009801, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34606501
6.
Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).
PLoS Negl Trop Dis
; 15(1): e0008912, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33412557
7.
Moxifloxacin in Pediatric Patients With Complicated Intra-abdominal Infections: Results of the MOXIPEDIA Randomized Controlled Study.
Pediatr Infect Dis J
; 37(8): e207-e213, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29356761